Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LOXL2 | Q9Y4K0 | 1/20 | 0.43 |
| ▸ | TRPA1 | O75762 | 1/20 | 0.41 |
| ▸ | CPA1 | P15085 | 1/20 | 0.41 |
| ▸ | FFAR1 | O14842 | 1/20 | 0.41 |
| ▸ | TAAR1 | Q96RJ0 | 2/20 | 0.40 |
| ▸ | IDO1 | P14902 | 3/20 | 0.39 |
| ▸ | AGXT | P21549 | 2/20 | 0.39 |
| ▸ | MAOA | P21397 | 1/20 | 0.39 |
| ▸ | MAOB | P27338 | 1/20 | 0.39 |
| ▸ | AOC3 | Q16853 | 1/20 | 0.38 |
| ▸ | DPP4 | P27487 | 4/20 | 0.38 |
| ▸ | DPP7 | Q9UHL4 | 3/20 | 0.38 |
| ▸ | FAP | Q12884 | 2/20 | 0.38 |
| ▸ | DPP8 | Q6V1X1 | 2/20 | 0.38 |
| ▸ | DPP9 | Q86TI2 | 2/20 | 0.38 |
| ▸ | TPH1 | P17752 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3393051 | 1.00 | LOXL2 (0.43) | LOXL2TRPA1CPA1FFAR1TAAR1 | |
| SCHEMBL2268272 | 1.00 | LOXL2 (0.43) | LOXL2TRPA1CPA1FFAR1TAAR1 | |
| SCHEMBL2269387 | 0.81 | GFER (0.42) | LOXL2TAAR1MAOAMAOBDPP4 | |
| SCHEMBL242929 | 0.81 | GFER (0.42) | LOXL2TAAR1MAOAMAOBDPP4 | |
| SCHEMBL242930 | 0.81 | GFER (0.42) | LOXL2TAAR1MAOAMAOBDPP4 | |
| SCHEMBL17559228 | 0.79 | IDO1 (0.39) | IDO1DPP4 | |
| SCHEMBL1972357 | 0.79 | FFAR1 (0.41) | FFAR1TAAR1IDO1AGXTDPP4 | |
| SCHEMBL8201384 | 0.79 | CYP1A2 (0.41) | IDO1DPP4DPP7FAPDPP8 | |
| SCHEMBL2267252 | 0.79 | SLC6A4 (0.59) | TAAR1IDO1AGXTAOC3DPP4 | |
| SCHEMBL7431808 | 0.79 | TAAR1 (0.40) | TAAR1IDO1DPP4DPP7FAP |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 157 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110195898-A1 | TREATMENT OF ALZHEIMER'S DISEASE AND MILD COGNITIVE IMPAIRMENT USING GNRH-I ANALOGS AND ONE OR MORE OF ACETYLCHOLINESTERASE INHIBITORS AND NMDA RECEPTOR ANTAGONISTS | VOYAGER PHARMACEUTICAL CORPORATION (US) | 2011-08-11 | — | — | US | claimed |
| US-20080171736-A1 | Treatment of Alzheimer's Disease and Mild Cognitive impairment using GnRH-I analogs and one or more of acetylcholinesterase inhibitors and NMDA receptor antagonists | VOYAGER PHARMACEUTICAL CORPORATION | 2008-07-17 | — | — | US | claimed |
| US-20060194737-A1 | Hepta-, octa-and nonapeptides having antiangiogenic activity | HAVIV FORTUNA | 2006-08-31 | — | — | US | claimed |
| US-7067490-B2 | Hepta-, Octa-and nonapeptides having antiangiogenic activity | ABBOTT LABORATORIES (US) | 2006-06-27 | — | — | US | claimed |
| EP-1232183-B1 | PEPTIDES HAVING ANTIANGIOGENIC ACTIVITY | ABBOTT LAB (US) | 2006-01-18 | — | — | EP | claimed |
| US-20050054581-A1 | Somatostatin antagonists and agonists that act at the sst subtype 2 receptor | HAY BRUCE A (US) | 2005-03-10 | — | — | US | claimed |
| EP-1451210-A2 | HEPTA-, OCTA- AND NONAPEPTIDES HAVING ANTIANGIOGENIC ACTIVITY | Abbott Laboratories (US) | 2004-09-01 | — | — | EP | claimed |
| US-6777535-B1 | USEFUL FOR TREATING CONDITIONS WHICH ARISE OR ARE EXACERBATED BY ANGIOGENESIS | ABBOTT LABORATORIES | 2004-08-17 | — | — | US | claimed |
| US-6753408-B1 | DRUGS USED FOR THERAPY | ABBVIE INC. | 2004-06-22 | — | — | US | claimed |
| EP-1421107-A1 | PEPTIDES HAVING ANTIANGIOGENIC ACTIVITY | Abbott Laboratories (US) | 2004-05-26 | — | — | EP | claimed |
| WO-1989007451-A1 | REDUCED SIZE LHRH ANALOGS | ABBOTT LABORATORIES (US) | 1989-08-24 | — | — | WO | claimed |
| EP-0328089-A2 | Reduced size LHRH analogs | ABBOTT LABORATORIES (US) | 1989-08-16 | — | — | EP | claimed |
| EP-0328090-A2 | LHRH analogs | ABBOTT LABORATORIES (US) | 1989-08-16 | — | — | EP | claimed |
| EP-0301850-A2 | LHRH antagonist analogs and 19-nor-progestational steroids for therapy | SYNTEX (U.S.A.) INC. (US) | 1989-02-01 | — | — | EP | claimed |
| EP-0277829-A2 | Nonapeptide and decapeptide analogs of LHRH as LHRH antagonists | SYNTEX (U.S.A.) INC. (US) | 1988-08-10 | — | — | EP | claimed |
| EP-0127899-B1 | CYCLIC PENTAPEPTIDES DISPLAYING SOMATOSTATIN ANTAGONISM AND METHOD OF TREATMENT OF MAMMALS THEREWITH | The Administrators of The Tulane University Educational Fund (US) | 1987-10-21 | — | — | EP | claimed |
| EP-0188214-A2 | Novel growth hormone-releasing peptides and method of treating mammals therewith | The Administrators of The Tulane University Educational Fund (US) | 1986-07-23 | — | — | EP | claimed |
| EP-0145768-A1 | CYCLIC PENTAPEPTIDES DISPLAYING SOMATOSTATIN ANTAGONISM AND METHOD OF TREATMENT OF MAMMALS THEREWITH | COY, David Howard (US) | 1985-06-26 | — | — | EP | claimed |
| WO-1984004916-A1 | CYCLIC PENTAPEPTIDES DISPLAYING SOMATOSTATIN ANTAGONISM AND METHOD OF TREATMENT OF MAMMALS THEREWITH | COY DAVID HOWARD (US) | 1984-12-20 | — | — | WO | claimed |
| EP-0127899-A1 | Cyclic pentapeptides displaying somatostatin antagonism and method of treatment of mammals therewith | The Administrators of The Tulane University Educational Fund (US) | 1984-12-12 | — | — | EP | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110195898-A1 | TREATMENT OF ALZHEIMER'S DISEASE AND MILD COGNITIVE IMPAIRMENT USING GNRH-I ANALOGS AND ONE OR MORE OF ACETYLCHOLINESTERASE INHIBITORS AND NMDA RECEPTOR ANTAGONISTS | GNRHR, GRIN1, GRIN3A | LOXL2 4664/4885TRPA1 4475/4885CPA1 667/4885 |
| US-20080171736-A1 | Treatment of Alzheimer's Disease and Mild Cognitive impairment using GnRH-I analogs and one or more of acetylcholinesterase inhibitors and NMDA receptor antagonists | GNRHR, GRIN1, GRIN3A | LOXL2 4664/4885TRPA1 4475/4885CPA1 667/4885 |
| US-20050054581-A1 | Somatostatin antagonists and agonists that act at the sst subtype 2 receptor | SSTR2, GHSR, SSTR3 | LOXL2 3258/4885TRPA1 354/4885CPA1 591/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.